Ascentage Pharma Group Valuation Multiples

Ascentage Pharma Group Overview

About Ascentage Pharma Group

Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.

Founded

2009

HQ

Employees

567

Website

ascentagepharma.com

Sectors

BiopharmaceuticalsBioTechDeepTech

Financials (LTM)

Revenue: $99M

EBITDA: ($154M)

EV

$2B

Valuation Multiples

Multiples.vc

Start free trial

Ascentage Pharma Group Financials

Ascentage Pharma Group reported last 12-month revenue of $99M and negative EBITDA of ($154M).

In the same LTM period, Ascentage Pharma Group generated $91M in gross profit, ($154M) in EBITDA losses, and had net loss of ($171M).

Ascentage Pharma Group P&L

In the most recent fiscal year, Ascentage Pharma Group reported revenue of $144M and EBITDA of ($35M).

Ascentage Pharma Group expects next 12-month revenue of XXX and NTM EBITDA of XXX

Ascentage Pharma Group Stock Performance

Ascentage Pharma Group has current market cap of $3B, and enterprise value of $2B.

Ascentage Pharma Group's stock price is $6.74.

Ascentage Pharma Group Valuation Multiples

Ascentage Pharma Group trades at 24.6x EV/Revenue multiple, and (15.9x) EV/EBITDA.

Ascentage Pharma Group Financial Valuation Multiples

As of April 20, 2026, Ascentage Pharma Group has market cap of $3B and EV of $2B.

Equity research analysts estimate Ascentage Pharma Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Ascentage Pharma Group has a P/E ratio of (14.7x).

Ascentage Pharma Group Margins & Growth Rates

Ascentage Pharma Group's revenue in the last 12 month grew by 56%.

Ascentage Pharma Group's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.3M for the same period.

Ascentage Pharma Group's rule of 40 is (27%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Ascentage Pharma Group's rule of X is 70% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Ascentage Pharma Group Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Ascentage Pharma Group M&A Activity

Ascentage Pharma Group acquired XXX companies to date.

Last acquisition by Ascentage Pharma Group was on XXXXXXXX, XXXXX. Ascentage Pharma Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Ascentage Pharma Group Investment Activity

Ascentage Pharma Group invested in XXX companies to date.

Ascentage Pharma Group made its latest investment on XXXXXXXX, XXXXX. Ascentage Pharma Group invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).